UK Bond Network presentation

RNS Number : 3609X

Venture Life Group PLC

23 November 2017

 

23 November 2017

VENTURE LIFE GROUP PLC

("Venture Life" or "the Company")

 UK Bond Network presentation

Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces it will be presenting at the upcoming UK Bond Network ("UKBN") investor event on Tuesday 28 November. The UKBN enables sophisticated, high net worth and professional investors to invest in bonds issued by quoted and unquoted British businesses. The event, in partnership with NEX Exchange and international law firm CMS, will feature three of UKBN's previous bond issuing businesses - and potentially a new listed borrower - each with a 15-minute slot to present their company.

Sharon Collins, Commercial Director of Venture Life Group will be giving an update on the Company to both existing and potential bondholders.

The event will take place at the NEX Exchange, 2 Broadgate Circle, London EC2M 7UR and will begin at 5.30pm. To register for the presentation, please use the following link:

https://www.eventbrite.co.uk/e/uk-bond-network-investor-evening-tickets-38491614455 

Venture Life Group PLC			[phone]
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Walbrook PR	[e-mail] or + 44 (0) 20 7933 8780
Anna Dunphy / Paul McManus		[phone] / [phone]

About Venture Life (www.venture-life.com) 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

END

 

 

NRABBBDBIGDBGRX